ALMS
$25.31
+$0.59 (2.42%)+2.42%
ClosedLoading chart...
IndexN/A
Market Cap3.12B
Enterprise Value8.25B
Income$-0.10B
Sales$0.02B
EmployeesN/A
P/E-6.46
P/S345.07
P/B27.54
P/C-22.42
EV/EBITDA-33.20
EV/SalesN/A
EPS (ttm)-3.92
EarningsN/A
Gross Margin85.46%
Oper. Margin-1776.32%
Profit Margin-1011.75%
Volume1.16M
Shs Outstand0.12B
Change3.69%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $3.15M | $0.00 | $250.00K |
| Gross Profit | $-3.15M | $0.00 | $-250.00K |
| Gross Margin | N/A | N/A | N/A |
| Operating Expenses | $297.60M | $158.17M | $113.60M |
| Operating Income | $-300.75M | $-158.17M | $-113.85M |
| Operating Margin | N/A | N/A | N/A |
| Net Income | $-294.23M | $-154.99M | $-111.93M |
| Net Margin | N/A | N/A | N/A |
| EPS (Basic) | $-10.38 | $-2.99 | $-14.93 |
| EBITDA | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A |
| Total Assets | $340.99M | $89.61M | $108.17M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A |
| Total Liabilities | $80.89M | $428.87M | $303.41M |
| Non-Equity Reserves | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A |
| Total Shareholders Equity | $260.10M | $-339.26M | $-195.24M |
| Accumulated Minority Interest | N/A | N/A | N/A |
| Total Equity | $260.10M | $-339.26M | $-195.24M |
| Total Liabilities & Stockholders Equity | $340.99M | $89.61M | $108.17M |
| Book Value Per Share | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Net Income | $-294.23M | $-154.99M | $-111.93M |
| Depreciation | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A |
| Cash from Operating Activities | $-255.08M | $-129.97M | $-107.72M |
| Capital Expenditures | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A |
Company coverage
Latest news
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterThe Motley Fool The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc. Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisGlobeNewswire Inc. Alumis Announces Pricing of Upsized Public Offering of Common StockGlobeNewswire Inc. Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for EnvudeucitinibThe Motley Fool Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque PsoriasisGlobeNewswire Inc. Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobeNewswire Inc. Alumis Misses Q2 Revenue as Costs JumpThe Motley Fool
Show 12 more stories
Alumis Completes Merger with ACELYRINBenzinga Alumis Stockholders Approve Merger with ACELYRINGlobeNewswire Inc. ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesGlobeNewswire Inc. ACELYRIN Reiterates Benefits of Value-Maximizing Combination with AlumisBenzinga Alumis and ACELYRIN Announce Amended Merger AgreementBenzinga Alumis and ACELYRIN Announce Amended Merger AgreementGlobeNewswire Inc. Alumis and ACELYRIN Announce Amended Merger AgreementGlobeNewswire Inc. Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerGlobeNewswire Inc. Alumis Reports Year End 2024 Financial Results and Highlights Recent AchievementsBenzinga Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGRGlobeNewswire Inc. Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisGlobeNewswire Inc. Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed MergerGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Discover more
You may be interested in